

Cu-Catalyzed Transamidation of Unactivated Aliphatic Amides

Vishal Kumar¹, Sanjeev Dhawan¹, Renu Bala¹, Sachin Balaso Mohite¹, Parvesh Singh^{2*} and Rajshekhar Karpoomath^{1,*}

¹Department of Pharmaceutical Chemistry, Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal (Westville), Durban-4000, South Africa.

²School of Chemistry and Physics, University of KwaZulu-Natal (Westville campus), Private Bag X01, Scottsville, Durban, South Africa

Table of contents

1. General information	S3
1.1 General Analytical Information.....	S3
1.2 General Reagents Information.....	S3
1.3 General Manipulation Considerations.....	S3
2. Optimization of Reaction Conditions of Transamidation.....	S4
2.1 General procedure for optimization of reaction conditions (Tables S1-S4).....	S4
3. Cu-catalyzed transamidation of aliphatic unactivated amides.....	
3.1 Experimental Procedure (EP-1).....	
3.2 Analytical Data.....	
4. Optimization of reaction conditions of annulation.....	S23
4.1 General procedure for optimizations of reaction conditions (Table S5).....	S23
5. Cu-catalyzed annulation of aliphatic unactivated amides with substituted 2-aminophenols.....	S24
5.1 Experimental Procedure (EP-2).....	S24
5.2 Analytical Data.....	S25
6. References.....	S31
7. Copies of ¹H and ¹³C spectra.....	S34

1.0 General Information

1.1 General Analytical Information. ^1H and ^{13}C NMR spectra were recorded on Bruker AV 400 MHz instrument at 400 MHz (^1H NMR), 100 MHz (^{13}C NMR). All ^1H NMR spectra were measured in parts per million (ppm) downfield, or were measured relative to the residual proton signals of d^1 -chloroform (CDCl_3 , 7.26 ppm) and dimethyl sulfoxide- d_6 ($\text{DMSO-}d_6$, 2.50 ppm). All ^{13}C NMR spectra were reported in ppm relative to residual carbon signals of CDCl_3 (77.16 ppm) and $\text{DMSO-}d_6$ (39.52 ppm). Coupling constants (J) are reported in hertz (Hz). Multiplicity was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), p (pentet), and m (multiplet). Thin-layer chromatography (TLC) was performed on precoated Merck Silica gel 60 F254 plates and compounds were visualized with a UV light at 254 nm. Flash chromatography for purification of compounds were carried out using silica gel (100–200 mesh).

1.2 General Reagents Information. Unless otherwise noted, commercially available materials were obtained from Aldrich Chemical Co., Alfa Aesar and used without prior purification. Chlorotrimethylsilane (TMSCl , 98% purity) was purchased from Aldrich Chemical Co. and was stored in refrigerator for storage. CuCl_2 (99% purity) was purchased from Aldrich Chemical Co. Lab reagent (LR) grade solvents were used for extraction and column chromatography purchased from Loba-chem.

1.3 General Manipulation Considerations. Unless otherwise specified, all reagents were weighed and handled in air, and all reactions performed in a 20 mL sealed vial with an air atmosphere. The eluents used for column chromatography were presented as ratios of solvent volumes. CuCl_2 (99% purity) was used for scope study unless otherwise noted. Yields reported in the publication are isolated yields unless otherwise noted. All new starting materials and products were characterized by ^1H and ^{13}C NMR spectroscopies.

2.0 Optimization of Reaction Conditions of transamidation

2.1 General procedure for optimizations of reaction conditions. An oven-dried 20 mL Teflon screw-capped vial equipped with a stir bar was sequentially charged with amide **1I**, aniline **2A** and catalyst. TMSCl were transferred into the tube via a syringe. The resulting mixture was stirred in a preheated heat block. After full fill the reaction condition of experiment, the reaction mixture was cooled down to room temperature. The reaction mixture was diluted with ethyl acetate and then washed with dilute aqueous HCl solution and saturated brine, dried with anhydrous Na₂SO₄, and finally concentrated in vacuo with the aid of rotary evaporator. The residue was purified by flash chromatography on silica gel using hexane and ethyl acetate as eluent to give the transamidated product **3I**.

Table S1:- Catalyst Study*

Entry	Catalyst (20 mol%)	Yield [#]
1	CuCl₂	72
2	CuBr ₂	61
3	CuCl	5
4	CuBr	4
5	CuI	3
6	Cu(OTf) ₂	41
7	Cu(OAc) ₂	52
8	PdCl ₂	traces
9	NiCl ₂	20

*Reaction conditions: **1I** (1.1 mmol), **2A** (1.61 mmol) and TMSCl (1.61 mmol) were reacted in Toluene (1.0 mL) at 120 °C for 10 h. [#]Isolation by using column chromatography.

Table S2:- Lewis acid study*

Entry	Lewis acid (Equiv)	Yield (%) [#]
1	TMSCl	72
2	FeCl ₃	13
3	AlCl ₃	9

4	TiCl ₄	traces
---	-------------------	--------

*Reaction conditions: 1I (1.1 mmol), 2A (1.61 mmol) and CuCl₂ (0.22 mmol) were reacted in Toluene (1.0 mL) at 120 °C for 10 h. #Isolation by using column chromatography.

Table S3:- Solvent-Study*

Entry	Solvent	Yield (%) [#]
1	Toluene	72
2	Xylene	69
3	NMP	79
4	DMSO	traces
5^s	Neat	87
6	Chlorobenzene	45
7	n-Butanol	0

*Reaction conditions: 1I (1.1 mmol), 2A (1.61 mmol) and CuCl₂ (0.22 mmol) were reacted in Toluene (1.0 mL) at 120 °C for 10 h. #Isolation by using column chromatography. ^sWithout solvent under same condition.

Table S4:- Equiv, time and temperature study*

Entry	Aniline 2A (equiv)	CuCl ₂ (mol%)	Temperature (°C)	TMSCl (equiv)	Time (hr)	Yield (%) [#]
1	1.0	20.0	120	1.5	10	56
2	1.5	20.0	120	1.5	10	87
3	2.0	20.0	120	1.5	10	88
4	1.5	0.0	120	1.5	10	10
5	1.5	10.0	120	1.5	10	70
6	1.5	15.0	120	1.5	10	81
7	1.5	30.0	120	1.5	10	86
8	1.5	40.0	120	1.5	10	87
9	1.5	20.0	80	1.5	10	0
10	1.5	20.0	100	1.5	10	35
11	1.5	20.0	110	1.5	10	72
12	1.5	20.0	130	1.5	10	85
13	1.5	20.0	140	1.5	10	88

14	1.5	20.0	120	0	10	0
15	1.5	20.0	120	0.5	10	10
16	1.5	20.0	120	1.0	10	55
17	1.5	20.0	120	2.0	10	89
18	1.5	20.0	120	1.5	2	60
19	1.5	20.0	120	1.5	4	87
20	1.5	20.0	120	1.5	6	85
21	1.5	20.0	120	1.5	8	89


*Reaction conditions: 1A (1.0 eq). #Isolation by using column chromatography.

3.0 Cu-catalyzed transamidation of Aliphatic unactivated amides

3.1 Experimental Procedure (EP-1): An oven-dried 20 mL Teflon screw-capped vial equipped with a stir bar was sequentially charged with aliphatic amide (0.5 mmol, 1 equiv.), amine (0.75 mmol, 1.5 equiv.) and CuCl₂ (0.075 mmol, 0.15 equiv.). TMSCl (0.75 mmol, 1.5 equiv.) was transferred into the tube via a syringe. The resulting mixture was stirred under an argon atmosphere in a preheated heat block at 120 °C for 4 h. At this point, the reaction mixture was cooled down to room temperature. The reaction mixture was diluted with ethyl acetate and then washed with dilute aqueous HCl solution (~0.1 M, 2 x 30 mL; **note:** water was used for washing instead of HCl (aq) for pyridine/quinoline-containing amide products) and saturated brine (~30 mL), dried with anhydrous Na₂SO₄, and finally concentrated in vacuo with the aid of rotary evaporator. The residue was purified by flash chromatography on silica gel using hexane and ethyl acetate as eluent to give the transamidated product.


Scheme 1

N-phenylformamide¹ (Scheme 1, entry 3A) (CAS No. 103-70-8)




Using the experimental procedure EP-1, the product was obtained as light brown solid in 94% yield; $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): $\delta = 9.20$ (br, 1H), 8.68 (d, $J = 11.3$ Hz, 1H), 8.57 (br, 1H), 8.31 (s, 1H), 7.56 (d, $J = 8.0$ Hz, 2H), 7.34-7.27 (m, 4H), 7.16 (t, $J = 7.5$ Hz, 1H), 7.12-7.08 (m, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): $\delta = 163.23, 159.89, 137.09, 136.85, 129.69, 129.01, 125.25, 124.74, 120.23, 118.78$.

N-(2-hydroxyphenyl)acetamide² (Scheme 1, entry 3B) (CAS No. 614-80-2)




Using the experimental procedure EP-1, the product was obtained as light brown solid in 92% yield; $^1\text{H NMR}$ (400 MHz, DMSO-d_6 , ppm): $\delta = 9.73$ (s, 1H), 9.30 (br, 1H), 7.67 (d, $J = 8.1$ Hz, 1H), 6.98 – 6.89 (m, 1H), 6.85 (d, $J = 9.5$ Hz, 1H), 6.75 (t, $J = 7.6$ Hz, 1H), 2.09 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, DMSO-d_6 , ppm): $\delta = 169.03, 147.90, 126.43, 124.66, 122.38, 118.98, 115.96, 23.60$.

N-(2-hydroxyphenyl)pentanamide³ (Scheme 1, entry 3C) (CAS No. 105293-97-8)




Using the experimental procedure EP-1, the product was obtained as light brown solid in 90% yield; $^1\text{H NMR}$ (400 MHz, DMSO-d_6 , ppm): $\delta = 9.72$ (br, 1H), 9.25 (s, 1H), 7.67 (d, $J = 9.3$ Hz, 1H), 6.94 (t, $J = 7.6$ Hz, 1H), 6.86 (d, $J = 6.6$ Hz, 1H), 6.76 (td, $J = 7.5, 1.6$ Hz, 1H), 2.40 (t, $J = 7.4$ Hz, 2H), 1.58 (p, $J = 7.4$ Hz, 2H), 1.33 (h, $J = 7.4$ Hz, 2H), 0.90 (t, $J = 7.3$ Hz, 3H). $^{13}\text{C NMR}$ (100 MHz, DMSO-d_6 , ppm): $\delta = 172.05, 147.92, 126.47, 124.64, 122.30, 118.99, 116.11, 35.68, 27.44, 21.80, 13.71$.

3,3-dimethyl-*N*-phenylbutanamide³ (Scheme 1, entry 3D) (CAS No. 72807-56-8)




Using the experimental procedure EP-1, the product was obtained as light brown solid in 86% yield; $^1\text{H NMR}$ (400 MHz, DMSO- d_6 , ppm): δ = 9.77 (s, 1H), 7.59 (d, J = 7.6 Hz, 2H), 7.01 (t, J = 7.3 Hz, 2H), 2.18 (s, 2H), 1.02 (s, 9H). $^{13}\text{C NMR}$ (100 MHz, DMSO- d_6 , ppm): δ = 169.96, 139.28, 128.59, 122.95, 119.18, 49.60, 30.83, 29.62.

N-phenylisobutyramide⁴ (Scheme 1, entry 3E) (CAS No. 4406-41-1)




Using the experimental procedure EP-1, the product was obtained as light brown solid in 85% yield; $^1\text{H NMR}$ (400 MHz, CDCl₃, ppm): δ = 7.53 (d, J = 8.3 Hz, 2H), 7.43 (br, 1H), 7.30 (t, J = 7.6 Hz, 2H), 7.09 (t, J = 7.4 Hz, 1H), 2.52 (hept, J = 7.0 Hz, 1H), 1.25 (s, 3H), 1.23 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl₃, ppm): δ = 175.72, 138.24, 129.00, 124.23, 120.11, 36.65, 19.69.

N-phenylpivalamide¹ (Scheme 1, entry 3F) (CAS No. 6625-74-7)



Using the experimental procedure EP-1, the product was obtained as light brown solid in 78% yield; $^1\text{H NMR}$ (400 MHz, CDCl₃, ppm): δ = 7.53 (d, J = 8.7 Hz, 2H), 7.31 (t, J = 7.5 Hz, 3H), 7.10 (t, J = 8.0 Hz, 1H), 1.32 (s, 9H). $^{13}\text{C NMR}$ (100 MHz, CDCl₃, ppm): δ = 176.72, 138.15, 129.01, 124.28, 120.16, 39.68, 27.71.


2,2,2-trichloro-*N*-phenylacetamide⁵ (Scheme 1, entry 3G) (CAS No. 2563-97-5)



Using the experimental procedure EP-1, the product was obtained as light brown solid in 50% yield; $^1\text{H NMR}$ (400 MHz, CDCl₃, ppm): δ = 8.34 (br, 1H), 7.58 (d, J = 8.7 Hz, 2H), 7.41 (t, J = 7.4 Hz, 2H),


7.24 (t, $J = 7.4$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): $\delta = 159.37, 136.06, 129.45, 126.18, 120.52, 92.96$.

***N*-phenylcyclopropanecarboxamide³** (Scheme 1, entry 3H) (CAS No. 2759-52-6)




Using the experimental procedure EP-1, the product was obtained as light brown solid in 86% yield; ^1H NMR (400 MHz, CDCl_3 , ppm): $\delta = 7.67$ (s, 1H), 7.50 (d, $J = 8.2$ Hz, 2H), 7.34 – 7.27 (m, 2H), 7.08 (t, $J = 7.5$ Hz, 1H), 1.55-1.49 (m, 1H), 1.13 – 0.97 (m, 2H), 0.83-0.79 (m, 2H).

***N*-phenylcyclohexanecarboxamide¹** (Scheme 1, entry 3I) (CAS No. 2719-26-8)




Using the experimental procedure EP-1, the product was obtained as light brown solid in 83% yield; ^1H NMR (400 MHz, DMSO-d_6 , ppm): $\delta = 9.79$ (s, 1H), 7.59 (d, $J = 8.2$ Hz, 2H), 7.26 (t, $J = 7.9$ Hz, 2H), 2.31 (t, $J = 11.6$ Hz, 1H), 1.83 – 1.70 (m, 4H), 1.65 (d, $J = 9.8$ Hz, 1H), 1.51 – 1.33 (m, 2H), 1.33 – 1.13 (m, 3H). ^{13}C NMR (100 MHz, DMSO-d_6 , ppm): $\delta = 174.29, 139.52, 128.60, 122.83, 119.02, 44.87, 29.15, 25.42, 25.26$.

***N*,2-diphenylacetamide³** (Scheme 1, entry 3J) (CAS No. 621-06-7)



Using the experimental procedure EP-1, the product was obtained as light brown solid in 87% yield; ^1H NMR (400 MHz, DMSO-d_6 , ppm): $\delta = 10.19$ (s, 1H), 7.61 (d, $J = 8.7$ Hz, 2H), 7.40 – 7.19 (m, 7H), 7.03 (t, $J = 7.4$ Hz, 1H), 3.64 (s, 2H). ^{13}C NMR (100 MHz, DMSO-d_6 , ppm): $\delta = 169.11, 139.25, 136.04, 129.12, 128.72, 128.31, 126.53, 123.21, 119.10, 43.35$.


2-phenoxy-N-phenylacetamide⁵ (Scheme 1, entry 3K) (CAS No. 18705-01-6)



Using the experimental procedure EP-1, the product was obtained as light brown solid in 89% yield; ¹H NMR (400 MHz, DMSO-d₆, ppm): δ = 10.11 (s, 1H), 7.65 (d, *J* = 8.0 Hz, 2H), 7.32 (t, *J* = 7.9 Hz, 4H), 7.08 (t, *J* = 7.4 Hz, 1H), 7.02-6.95 (m, 3H), 4.70 (s, 2H). ¹³C NMR (100 MHz, DMSO-d₆, ppm): δ = 166.59, 157.83, 138.41, 129.53, 128.74, 123.70, 121.19, 119.71, 114.66, 67.10.


Scheme 2

***N*-(2-Hydroxy-4-methylphenyl)formamide**⁶ (Scheme 2, entry 3a) (CAS No. 2843-27-8)



Using the experimental procedure EP-1, the product was obtained as brown solid in 73% yield; 66:34 mixture of rotamers: ¹H NMR (400 MHz, CDCl₃, ppm): δ = 8.66 (d, *J* = 11.1 Hz, 0.47H), 8.45 (s, 1H), 8.35 (d, *J* = 8.3 Hz, 1H), 7.74 (br, 1.3H), 7.38 (d, *J* = 8.1 Hz, 0.45H), 7.33 (d, *J* = 8.1 Hz, 1H), 7.27 – 7.18 (m, 1H), 7.09 (dt, *J* = 8.3, 4.4 Hz, 0.48H), 7.02 (t, *J* = 7.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃, ppm): δ = 161.73, 159.03, 133.81, 130.44, 129.24, 128.13, 127.93, 126.10, 125.27, 122.14, 118.87.


***N*-(3-chlorophenyl) formamide**⁷ (Scheme 2, entry 3b) (CAS No. 139-71-9)



Using the experimental procedure EP-1, the product was obtained as off white solid in 90%; 55:45 mixture of rotamers: ¹H NMR (400 MHz, CDCl₃, ppm): δ = 8.69 – 8.61 (m, 2H), 8.56 (s, 0H), 8.33 (s,


1H), 7.70 (s, 0H), 7.62 (s, 1H), 7.35 (d, $J = 8.1$ Hz, 1H), 7.28 – 7.15 (m, 4H), 7.12 (d, $J = 8.1$ Hz, 1H), 7.06 (d, $J = 7.0$ Hz, 2H), 6.95 (d, $J = 7.9$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): $\delta = 162.60$, 159.26, 138.08, 135.60, 134.88, 130.95, 130.25, 125.50, 125.05, 120.25, 118.92, 118.08, 116.84.

***N*-(4-chlorophenyl) formamide**⁶ (Scheme 2, entry 3c) (CAS No. 2617-79-0)




Using the experimental procedure EP-1, the product was obtained as off-white solid in 80% yield; 56:44 mixture of rotamers: ^1H NMR (400 MHz, CDCl_3 , ppm): $\delta = 8.71$ (br, 0.64H), 8.59 (d, $J = 11.2$ Hz, 0.77H), 8.31 (s, 1H), 7.75 (br, 0.82H), 7.44 (d, $J = 8.9$ Hz, 2H), 7.26 (d, $J = 8.8$ Hz, 1.58H), 7.22 (d, $J = 8.8$ Hz, 2H), 6.99 (d, $J = 8.8$ Hz, 1.56H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): $\delta = 162.83$, 159.34, 135.54, 135.42, 130.91, 129.99, 129.95, 129.24, 121.40, 120.20.

***N*-(3-fluorophenyl)formamide**⁸ (Scheme 2, entry 3d) (CAS No. 1428-10-0)




Using the experimental procedure EP-1, the product was obtained as yellow solid in 87% yield; 52:48 mixture of rotamers: ^1H NMR (400 MHz, CDCl_3 , ppm): $\delta = 8.88$ (br, 0.88H), 8.64 (d, $J = 11.2$ Hz, 0.95H), 8.30 (s, 1.17H), 8.03 (br, 1.06H), 7.41 (d, $J = 10.6$ Hz, 1.15H), 7.28 – 7.10 (m, 3.35H), 6.78 (m, 3.96H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): $\delta = 164.68$, 164.20, 162.83, 162.22, 161.77, 159.59, 138.59, 138.52, 138.41, 131.29, 131.20, 130.39, 130.29, 115.41, 115.38, 114.18, 114.15, 112.24, 112.03, 111.78, 111.57, 107.89, 107.63, 106.16, 105.91.

***N*-(4-fluorophenyl) formamide**⁶ (Scheme 2, entry 3e) (CAS No. 459-25-6)




Using the experimental procedure EP-1, the product was obtained as off-white solid in 69% yield; 63:37 mixture of rotamers: $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): δ = 8.63 (br, 0.55H), 8.57 (d, J = 11.1 Hz, 0.82H), 8.34 (s, 1H), 7.76 (br, 0.86H), 7.50 (dd, J = 9.0, 4.9 Hz, 2H), 7.07 (m, 2.87H), 7.01 (t, J = 8.6 Hz, 2.14H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): δ = 163.20, 161.80, 160.95, 159.37, 159.30, 158.52, 133.00, 132.86, 122.04, 121.95, 121.34, 121.26, 116.79, 116.56, 116.00, 115.77.

N-(2-methoxyphenyl)formamide⁶ (Scheme 2, entry 3f) (CAS No. 23896-88-0)



Using the experimental procedure EP-1, the product was obtained as brown solid in 92% yield; 69:31 mixture of rotamers: $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): δ = 8.89 (s, 0.25H), 8.47 (s, 1H), 8.35 (d, J = 7.9 Hz, 1H), 7.92 (s, 0.82H), 7.79 (s, 0.41H), 7.18 (d, J = 8.2 Hz, 0.43H), 7.12 (t, J = 7.9 Hz, 0.46H), 7.06 (t, J = 7.1 Hz, 1H), 6.99 – 6.85 (m, 3H), 3.87 (s, 3H), 3.85 (s, 1.29H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): δ = 161.60, 158.91, 148.89, 147.91, 126.81, 126.29, 125.34, 124.36, 121.14, 120.55, 116.85, 111.39, 110.16, 55.80.


N-(4-methoxyphenyl)formamide⁶ (Scheme 2, entry 3g) (CAS No. 5470-34-8)



Using the experimental procedure EP-1, the product was obtained as reddish brown solid in 93% yield; 51:49 mixture of rotamers: $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): δ = 8.55 (br, 0.63H), 8.50 (d, J = 11.4


Hz, 1H), 8.28 (s, 1H), 7.88 (br, 0.83H), 7.43 (d, $J = 9.0$ Hz, 2H), 7.03 (d, $J = 8.8$ Hz, 1.91H), 6.85 (dd, $J = 14.4, 8.9$ Hz, 4H), 3.78 (s, 2.86H), 3.76 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 163.43, 159.34, 157.68, 156.77, 130.14, 129.74, 121.96, 121.61, 114.97, 114.29, 55.63, 55.55.

N-(2-Hydroxy-4-methylphenyl)formamide⁹ (Scheme 2, entry 3h) (CAS No. 2843-27-8)




Using the experimental procedure EP-1, the product was obtained as brown solid in 90% yield; 85:15 mixture of rotamers: ^1H NMR (400 MHz, DMSO-d_6 , ppm): $\delta = 9.93$ (s, 1H), 9.56 (s, 1H), 9.24 (d, $J = 11.1$ Hz, 0.15H), 8.52 (d, $J = 11.2$ Hz, 0.17H), 8.28 (s, 1H), 8.02 (d, $J = 7.9$ Hz, 1H), 7.12 (d, $J = 7.7$ Hz, 0.17H), 6.98 (t, $J = 7.6$ Hz, 0.19H), 6.94 – 6.82 (m, 2H), 6.75 (t, $J = 7.6$ Hz, 1.2H). ^{13}C NMR (100 MHz, DMSO-d_6 , ppm): $\delta = 163.48, 160.04, 148.97, 146.74, 126.01, 125.49, 124.20, 121.77, 120.84, 119.45, 119.01, 116.11, 115.11$.

N-(3-hydroxyphenyl)formamide⁷ (Scheme 2, entry 3i) (CAS No. 24891-35-8)




Using the experimental procedure EP-1, the product was obtained as brown oil in 89% yield; 73:27 mixture of rotamers: ^1H NMR (400 MHz, DMSO-d_6 , ppm): $\delta = 10.03$ (s, 1H), 10.00 (s, 0.25H), 9.51 (s, 0.37H), 9.41 (s, 1H), 8.72 (d, $J = 11.0$ Hz, 0.36H), 8.22 (s, 1H), 7.18 (s, 1H), 7.08 (t, $J = 8.1$ Hz, 1.44H), 6.93 (d, $J = 10.0$ Hz, 1H), 6.63 (d, $J = 7.9$ Hz, 0.38H), 6.57 (s, 0.38H), 6.48 (t, $J = 7.0$ Hz, 0.39H). ^{13}C NMR (100 MHz, DMSO-d_6 , ppm): $\delta = 162.38, 159.46, 158.27, 157.70, 139.47, 139.25, 130.20, 129.57, 110.85, 110.80, 109.92, 108.02, 106.40, 104.77$.

N-(4-hydroxyphenyl)formamide⁹ (Scheme 2, entry 3j) (CAS No. 41656-75-1)




Using the experimental procedure EP-1, the product was obtained as brown solid in 93% yield; 77:23 mixture of rotamers: $^1\text{H NMR}$ (400 MHz, DMSO- d_6 , ppm): δ = 9.88 (s, 1H), 9.83 (d, J = 11.2 Hz, 0.34H), 9.22 (s, 1.28H), 8.50 (d, J = 11.1 Hz, 0.28H), 8.16 (d, J = 2.2 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 6.98 (d, J = 8.8 Hz, 0.61H), 6.76 – 6.66 (m, 2.63H). $^{13}\text{C NMR}$ (100 MHz, DMSO- d_6 , ppm): δ = 162.56, 158.84, 154.23, 153.55, 129.99, 129.66, 120.82, 120.22, 115.87, 115.19.

N-(4-(methylthio)phenyl)formamide⁹ (Scheme 2, entry 3k) (CAS No. 170288-29-6)



Using the experimental procedure EP-1, the product was obtained as cream solid in 88% yield; 54:46 mixture of rotamers: $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): δ = 8.57 (d, J = 11.4 Hz, 0.92H), 8.51 (br, 0.7H), 8.29 (s, 1H), 7.61 (br, 0.83H), 7.42 (d, J = 8.7 Hz, 2H), 7.23 – 7.13 (m, 4H), 6.98 (d, J = 8.6 Hz, 1.80H), 2.41 (s, 2.56H), 2.40 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): δ = 162.82, 159.24, 135.43, 134.51, 134.47, 134.22, 128.52, 127.95, 120.76, 119.76, 16.60, 16.58.


N-*m*-tolylformamide⁶ (Scheme 2, entry 3l) (CAS No. 3085-53-8)



Using the experimental procedure EP-1, the product was obtained as brown oil in 85% yield; 55:45 mixture of rotamers: $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): δ = 8.96 (br, 0.86H), 8.68 (d, J = 11.3 Hz,


1H), 8.33 (d, $J = 1.9$ Hz, 0.8H), 8.09 (br, 0.66H), 7.40 (s, 0.82H), 7.33 (d, $J = 8.1$ Hz, 0.79H), 7.20 (dt, $J = 12.0, 7.8$ Hz, 1.88H), 6.99 (d, $J = 7.7$ Hz, 1H), 6.96 – 6.88 (m, 2.87H), 2.34 (s, 3.15H), 2.31 (s, 2.52H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): $\delta = 163.16, 159.57, 139.87, 139.06, 137.01, 136.82, 129.57, 128.91, 126.10, 125.61, 120.80, 119.55, 117.24, 115.81, 21.48, 21.42$.

N-(3-acetylphenyl)formamide⁹ (Scheme 2, entry 3m) (CAS No. 72801-78-6)




Using the experimental procedure EP-1, the product was obtained as white solid in 72% yield; 64:36 mixture of rotamers: ^1H NMR (400 MHz, CDCl_3 , ppm): $\delta = 8.99$ (br, 0.52H), 8.86 (d, $J = 11.1$ Hz, 0.6H), 8.43 (s, 1H), 8.39 (br, 0.71H), 7.96-7.90 (m, 3.17H), 7.67 (d, $J = 8.7$ Hz, 2H), 7.18 (d, $J = 8.7$ Hz, 1.24H), 2.57 (s, 1.72H), 2.56 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): $\delta = 197.39, 197.01, 162.26, 159.61, 141.55, 141.36, 133.74, 133.28, 130.51, 129.86, 119.39, 117.34, 26.56$.

N-(4-acetylphenyl)formamide⁵ (Scheme 2, entry 3n) (CAS No. 41656-75-1)




Using the experimental procedure EP-1, the product was obtained as white solid in 80% yield; 66:34 mixture of rotamers: ^1H NMR (400 MHz, CDCl_3 , ppm): $\delta = 8.93$ (d, $J = 11.4$ Hz, 0.46H), 8.76 (d, $J = 11.2$ Hz, 0.54H), 8.48 (br, 0.75H), 8.42 (s, 1H), 8.07 (s, 1H), 7.92 (d, $J = 8.1$ Hz, 1H), 7.73 (d, $J = 7.5$ Hz, 1.14H), 7.67 (d, $J = 9.3$ Hz, 1H), 7.52 – 7.37 (m, 1.57H), 7.32 (d, $J = 5.6$ Hz, 0.55H), 2.60 (s, 1.56H), 2.57 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): $\delta = 198.34, 197.66, 162.74, 159.83, 138.53, 137.81, 137.78, 137.61, 130.19, 129.53, 125.29, 124.85, 124.69, 123.20, 119.42, 117.84, 26.81$.

4-formamidobenzoic acid⁵ (Scheme 2, entry 3o) (CAS No. 28533-43-9)




Using the experimental procedure EP-1, the product was obtained as brown oil in 68% yield; 55:45 mixture of rotamers: ¹H NMR (400 MHz, CDCl₃, ppm): δ = 8.85 (br, 0.49H), 8.69 (d, *J* = 11.4 Hz, 0.58H), 8.35 (s, 0.49H), 8.00 (br, 0.45H), 7.55 (d, *J* = 8.2 Hz, 1H), 7.33 (dt, *J* = 13.4, 8.1 Hz, 2.15H), 7.18 (t, *J* = 7.5 Hz, 0.57H), 7.12 (m, 1.6H). ¹³C NMR (100 MHz, CDCl₃, ppm): δ = 163.09, 159.55, 137.06, 136.87, 129.82, 129.15, 125.37, 124.87, 120.19, 118.91.

Ethyl 4-formamidobenzoate⁵ (Scheme 2, entry 3p) (CAS No. 5422-63-9)




Using the experimental procedure EP-1, the product was obtained as white solid in 60% yield; 75:25 mixture of rotamers: ¹H NMR (400 MHz, DMSO-d₆, ppm): δ = 10.53 (s, 1H), 10.46 (d, *J* = 10.8 Hz, 0.27H), 8.96 (d, *J* = 10.6 Hz, 0.26H), 8.35 (d, *J* = 1.7 Hz, 1H), 7.91 (m, 2.65H), 7.71 (d, *J* = 8.4 Hz, 2H), 7.31 (d, *J* = 8.1 Hz, 0.77H), 4.28 (q, *J* = 7.1 Hz, 2.64H), 1.30 (t, *J* = 7.1 Hz, 4H). ¹³C NMR (100 MHz, DMSO-d₆, ppm): δ = 165.24, 162.54, 160.11, 142.90, 142.43, 130.73, 130.33, 124.66, 118.62, 116.43, 60.45, 14.18.

***N*-(2,4-dimethylphenyl)formamide¹⁰** (Scheme 2, entry 3q) (CAS No. 60397-77-5)




Using the experimental procedure EP-1, the product was obtained as off-white solid in 79% yield; 65:35 mixture of rotamers: $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): δ = 8.45 (d, J = 11.2 Hz, 0.91H), 8.39 (s, 0.53H), 8.18 (br, 0.77H), 7.66 (d, J = 8.7 Hz, 0.51H), 7.35 (br, 0.38H), 7.04 (s, 1H), 7.00 (s, 3H), 2.31 (s, 3H), 2.28 (s, 1.62H), 2.26 (s, 3H), 2.22 (s, 1.65H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): δ = 163.82, 159.50, 136.07, 135.45, 132.53, 131.96, 131.31, 130.22, 129.26, 127.63, 127.36, 123.51, 121.46, 20.94, 20.87, 17.79, 17.75.

***N*-(2-bromo-4-methylphenyl)formamide⁹** (Scheme 2, entry 3r) (CAS No. 353284-16-9)




Using the experimental procedure EP-1, the product was obtained as off-white solid in 65% yield; 67:33 mixture of rotamers: $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): δ = 8.62 (d, J = 11.1 Hz, 0.49H), 8.46 (s, 1H), 8.22 (d, J = 8.3 Hz, 1H), 7.62 (br, 1H), 7.42 (s, 0.50H), 7.37 (s, 1H), 7.12 (s, 1H), 7.10 (s, 0.58H), 2.32 (s, 1.48H), 2.30 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): δ = 161.90, 158.88, 136.91, 135.93, 133.88, 132.72, 132.35, 129.42, 129.17, 122.24, 119.46, 114.78, 113.04, 20.67, 20.61.

***N*-(3-chloro-4-fluorophenyl)formamide⁹** (Scheme 2, entry 3s) (CAS No. 770-22-9)




Using the experimental procedure EP-1, the product was obtained as off-white solid in 79% yield; 64:36 mixture of rotamers: $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): δ = 8.66 (br, 0.42H), 8.58 (d, J = 11.1 Hz, 0.56H), 8.35 (s, 1H), 7.78 (br, 0.73H), 7.72 (dd, J = 6.5, 2.5 Hz, 1H), 7.36 (m, 1H), 7.18 (dd, J = 6.2, 2.6 Hz, 0.49H), 7.14 (t, J = 8.6 Hz, 0.57H), 7.08 (t, J = 8.7 Hz, 1H), 7.03 – 6.94 (m, 0.56H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): δ = 162.89, 159.30, 157.27, 156.42, 154.80, 153.97, 133.55, 122.47, 121.61, 119.88, 119.81, 119.13, 119.06, 117.81, 117.58, 117.00, 116.78.

N-(5-(*tert*-butyl)-2-hydroxyphenyl)formamide⁵ (Scheme 2, entry 3t) (CAS No. 2305056-85-1)



Using the experimental procedure EP-1, the product was obtained as brown solid in 87% yield; 77:23 mixture of rotamers: $^1\text{H NMR}$ (400 MHz, DMSO-d_6 , ppm): δ = 9.67 (s, 1H), 9.53 (s, 1H), 9.18 (d, J = 11.2 Hz, 0.14H), 8.52 (d, J = 11.2 Hz, 0.17H), 8.27 (s, 1H), 8.08 (s, 1H), 7.09 (s, 0.18H), 6.99 (dd, J = 8.5, 2.4 Hz, 0.2H), 6.93 (dd, J = 8.4, 2.4 Hz, 1H), 6.82 (s, 0.21H), 6.78 (d, J = 8.4 Hz, 1H), 1.23 (s, 11.58H). $^{13}\text{C NMR}$ (100 MHz, DMSO-d_6 , ppm): δ = 163.64, 159.98, 146.67, 144.42, 141.89, 141.26, 125.41, 124.54, 122.04, 120.81, 119.06, 117.92, 115.62, 114.64, 33.79, 31.37, 31.29.


N-(2-hydroxy-5-methylphenyl)formamide⁵ (Scheme 2, entry 3u) (CAS No. 74642-14-1)



Using the experimental procedure EP-1, the product was obtained as brown solid in 85% yield; 81:19 mixture of rotamers: $^1\text{H NMR}$ (400 MHz, DMSO-d_6 , ppm): δ = 9.65 (s, 1H), 9.50 (s, 1H), 9.18 (d, J = 11.6 Hz, 0.15H), 8.51 (d, J = 11.1 Hz, 0.17H), 8.26 (s, 1H), 7.86 (s, 1H), 6.93 (s, 0.18H), 6.76 (d, J =


6.7 Hz, 0.63H), 6.73 (m, 1.8H), 2.18 (s, 3.72H). ^{13}C NMR (100 MHz, DMSO- d_6 , ppm): δ = 163.40, 159.93, 146.52, 144.40, 128.16, 127.53, 124.98, 124.44, 122.12, 121.26, 115.96, 114.89, 20.49, 20.09.

N-(2-methoxyphenyl)acetamide¹¹ (Scheme 2, entry 3v) (CAS No. 93-26-5)




Using the experimental procedure EP-1, the product was obtained as white solid in 93% yield; ^1H NMR (400 MHz, CDCl₃, ppm): δ = 8.34 (d, J = 9.7 Hz, 1H), 7.79 (br, 1H), 7.08 – 6.99 (m, 1H), 6.94 (t, J = 7.1 Hz, 1H), 6.86 (d, J = 8.2 Hz, 1H), 3.87 (s, 3H), 2.19 (s, 3H). ^{13}C NMR (100 MHz, CDCl₃, ppm): δ = 168.31, 147.79, 127.78, 123.73, 121.17, 119.92, 109.98, 55.74, 24.97.

N-(3-nitrophenyl)acetamide¹² (Scheme 2, entry 3w) (CAS No. 121-89-1)




Using the experimental procedure EP-1, the product was obtained as yellow solid in 53% yield; ^1H NMR (400 MHz, DMSO- d_6 , ppm): δ = 10.44 (br, 1H), 8.60 (t, J = 2.2 Hz, 1H), 7.87 (dd, J = 8.2, 2.2 Hz, 2H), 7.57 (t, J = 8.2 Hz, 1H), 2.09 (s, 3H). ^{13}C NMR (100 MHz, DMSO- d_6 , ppm): δ = 169.10, 147.95, 140.40, 130.08, 124.87, 117.50, 113.04, 112.94, 24.03.

N-(3-(trifluoromethyl)phenyl)acetamide⁵ (Scheme 2, entry 3x) (CAS No. 349-76-8)




Using the experimental procedure EP-1, the product was obtained as white solid in 74% yield; $^1\text{H NMR}$ (400 MHz, DMSO- d_6 , ppm): δ = 10.26 (s, 1H), 8.07 (t, J = 2.0 Hz, 1H), 7.75 (d, J = 8.2 Hz, 1H), 7.52 (t, J = 8.0 Hz, 1H), 7.36 (d, J = 7.7 Hz, 1H), 2.07 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, DMSO- d_6 , ppm): δ = 168.93, 140.04, 129.91, 122.46, 119.36, 119.32, 119.29, 119.25, 115.0, 114.96, 24.02, 20.57.

N-(4-(trifluoromethoxy)phenyl)acetamide⁵ (Scheme 2, entry 3y) (CAS No. 85013-98-5)




Using the experimental procedure EP-1, the product was obtained as Colourless Solid in 60% yield; $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): δ = 7.95 (s, 1H), 7.53 (d, J = 9.0 Hz, 2H), 7.14 (d, J = 8.8 Hz, 2H), 2.16 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): δ = 169.00, 136.71, 121.77, 121.32, 42.44, 24.46.

N-(4-chlorophenyl)acetamide⁵ (Scheme 2, entry 3z) (CAS No. 99-91-2)




Using the experimental procedure EP-1, the product was obtained as light yellow solid in 68%; $^1\text{H NMR}$ (400 MHz, DMSO- d_6 , ppm): δ = 10.05 (br, 1H), 7.60 (d, J = 8.8 Hz, 2H), 7.33 (d, J = 8.9 Hz, 2H), 2.04 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, DMSO- d_6 , ppm): δ = 168.43, 138.26, 128.53, 126.50, 120.48, 23.96.

N-methyl-*N*-phenylformamide⁶ (Scheme 2, entry 3aa) (CAS No. 93-61-8)




Using the experimental procedure EP-1, the product was obtained as yellow oil in 87% yield; $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): $\delta = 8.34$ (s, 1H), 7.28 (t, $J = 8.0$ Hz, 2H), 7.14 (t, $J = 8.0$ Hz, 1H), 7.04 (d, $J = 8.6$ Hz, 2H), 3.18 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): $\delta = 162.41$, 142.21, 129.66, 126.46, 122.41, 32.08.

N,N-diphenylformamide⁵ (Scheme 2, entry 3ab) (CAS No. 607-00-1)




Using the experimental procedure EP-1, the product was obtained as yellow solid in 79% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): $\delta = 8.60$ (s, 1H), 7.33-7.30 (m, 4H), 7.28 – 7.15 (m, 4H), 7.10 (d, $J = 7.9$ Hz, 2H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): $\delta = 161.85$, 141.91, 139.76, 129.81, 129.29, 127.16, 126.97, 126.23, 125.21.

1-(4-(2-chlorophenyl)piperazin-1-yl)ethan-1-one⁵ (Scheme 2, entry 3ac) (CAS No. 150557-82-7)




Using the experimental procedure EP-1, the product was obtained as light yellow solid in 85%; $^1\text{H NMR}$ (400 MHz, DMSO-d_6 , ppm): $\delta = 7.42$ (d, $J = 7.8$ Hz, 1H), 7.30 (t, $J = 7.7$ Hz, 1H), 7.14 (d, $J = 8.1$ Hz, 1H), 7.06 (t, $J = 7.6$ Hz, 1H), 3.58 (q, $J = 4.9$ Hz, 4H), 2.96 (t, $J = 4.9$ Hz, 2H), 2.90 (t, $J = 5.0$ Hz, 2H), 2.04 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, DMSO-d_6 , ppm): $\delta = 168.33$, 148.65, 130.31, 128.09, 127.73, 124.23, 121.09, 51.16, 50.74, 45.91, 45.48, 41.03, 21.19.

*morpholine-4-carbaldehyde*⁶ (Scheme 2, entry 3ad) (CAS No. 4394-85-8)




Using the experimental procedure EP-1, the product was obtained as yellow oil in 75%; $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): $\delta = 7.86$ (s, 1H), 3.51-3.48 (m, 2H), 3.48 – 3.41 (m, 2H), 3.40 – 3.32 (m, 2H), 3.26 – 3.18 (m, 2H). $^{13}\text{C NMR}$ (100 MHz, DMSO-d_6 , ppm): $\delta = 160.56, 66.85, 66.01, 45.42, 40.20$.

*piperidine-1-carbaldehyde*⁶ (Scheme 2, entry 3ae) (CAS No. 2591-86-8)




Using the experimental procedure EP-1, the product was obtained as yellow oil in 69%; $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): $\delta = 7.79$ (s, 1H), 3.30 – 3.21 (m, 2H), 3.17 – 3.03 (m, 2H), 1.50 – 1.45 (m, 2H), 1.42 – 1.34 (m, 2H), 1.35 – 1.24 (m, 2H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): $\delta = 160.33, 46.34, 40.11, 26.14, 24.66, 24.23$.

*N-(quinolin-8-yl)formamide*⁵ (Scheme 2, entry 3af) (CAS No. 62937-22-8)



Using the experimental procedure EP-1, the product was obtained as brown solid in 60% yield; 88:12 mixture of rotamers; $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): $\delta = 9.62$ (br, 1H), 9.20 (br, 0.09H), 8.87 (d, $J = 11.7$ Hz, 0.11H), 8.56 (dd, $J = 4.3, 1.6$ Hz, 1.13H), 8.50 (p, $J = 4.6$ Hz, 1H), 8.45 (s, 1H), 7.93 (d, $J = 8.3$ Hz, 1H), 7.89 (d, $J = 8.1$ Hz, 0.15H), 7.29 (s, 1.15H), 7.28 (s, 1H), 7.26 (s, 0.18H), 7.22 (dd, $J = 8.3, 4.3$ Hz, 1.31H), 7.01 (s, 0.1H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): $\delta = 159.39, 148.30, 138.05, 136.88, 133.52, 128.12, 127.51, 122.37, 121.81, 117.99$.

N-(pyridin-2-yl)formamide⁹ (Scheme 2, entry 3ag) (CAS No. 34813-97-3)



Using the experimental procedure EP-1, the product was obtained as brown solid in 70%; ¹H NMR (400 MHz, DMSO-d₆, ppm): δ = 10.58 (s, 1H), 9.28 (d, *J* = 10.3 Hz, 0.57H), 8.33 (s, 0.82H), 8.25 (s, 0.64H), 7.82 – 7.69 (m, 1.11H), 7.08 (d, *J* = 5.6 Hz, 1.11H), 6.92 (d, *J* = 8.3 Hz, 0.61H). ¹³C NMR (100 MHz, DMSO-d₆, ppm): δ = 162.14, 160.32, 151.65, 151.03, 148.08, 138.71, 138.33, 119.78, 119.24, 113.79, 111.14.

4.0 Optimization of Reaction Conditions of annulation

4.1 General procedure for optimizations of reaction conditions. An oven-dried 20 mL Teflon screw-capped vial equipped with a stir bar was sequentially charged with amide **4c**, aniline **5a** and catalyst. TMSCl were transferred into the tube via a syringe. The resulting mixture was stirred in a preheated heat block. After full fill the reaction condition of experiment, the reaction mixture was cooled down to room temperature. The reaction mixture was diluted with ethyl acetate and then washed with dilute aqueous HCl solution and saturated brine, dried with anhydrous Na₂SO₄, and finally concentrated in vacuo with the aid of rotary evaporator. The residue was purified by flash chromatography on silica gel using hexane and ethyl acetate as eluent to give the transamidated product **6c**.

Table S5:- Equiv, time and temperature study*

Entry	Aniline 5a (equiv)	CuCl ₂ (mol%)	Temperature (°C)	TMSCl (equiv)	Time (hr)	Yield (%) [#]
1	1.5	20.0	100	1.5	12	0
2	1.5	20.0	110	1.5	12	0

3	1.5	20.0	130	1.5	12	11
4	1.5	20.0	140	1.5	12	17
5	1.5	20.0	150	1.5	12	45
6	1.5	20.0	160	1.5	12	51
7	1.5	20.0	160	1.5	14	61
8	1.5	20.0	160	1.5	16	65
9	1.5	20.0	160	1.5	18	65
10	1.5	20.0	160	1.5	20	64
11	1.5	20.0	160	0	16	0
12	1.5	20.0	160	0.5	16	8
13	1.5	20.0	160	1.0	16	40
14	1.5	20.0	160	2.0	16	76


*Reaction conditions: 4c (1.0 eq). #Isolation by using column chromatography.

5.0 Cu-catalyzed annulation of aliphatic unactivated amides with substituted 2-aminophenols

5.1 Experimental Procedure (EP-2): An oven-dried 20 mL Teflon screw-capped vial equipped with a stir bar was sequentially charged with aliphatic amide (0.5 mmol, 1 equiv.), amine (0.75 mmol, 1.5 equiv.) and CuCl₂ (0.075 mmol, 0.15 equiv.). TMSCl (0.75 mmol, 1.5 equiv.) was transferred into the tube via a syringe. The resulting mixture was stirred under an argon atmosphere in a preheated heat block at 160 °C for 16 h. At this point, the reaction mixture was cooled down to room temperature. The reaction mixture was diluted with ethyl acetate and then washed with dilute aqueous HCl solution (~0.1 M, 2 x 30 mL; **note:** water was used for washing instead of HCl (aq) for pyridine/quinoline-containing amide products) and saturated brine (~30 mL), dried with anhydrous Na₂SO₄, and finally concentrated in vacuo with the aid of rotary evaporator. The residue was purified by flash chromatography on silica gel using hexane and ethyl acetate as eluent to give the annulated benzoxazole product.


5.2 Analytical Data

2-methylbenzo[d]oxazole¹³ (Scheme 5a, entry 6a) (CAS No. 95-21-6)




Using the experimental procedure EP-2, the product was obtained as light brown liquid in 80%; ¹H NMR (400 MHz, CDCl₃, ppm): δ = 7.66 (dd, J = 6.2, 2.9 Hz, 1H), 7.47 (dd, J = 6.4, 2.9 Hz, 1H), 7.29 (dd, J = 5.3, 3.9 Hz, 2H), 2.65 (s, 3H). ¹³C NMR (100 MHz, DMSO-d₆, ppm): δ = 172.1, 145.4, 140.6, 138.2, 128.7, 122.9, 23.5.

2-propylbenzo[d]oxazole¹⁴ (Scheme 5a, entry 6b) (CAS No. 2008-05-1)




Using the experimental procedure EP-2, the product was obtained as light brown liquid in 76%; ¹H NMR (400 MHz, CDCl₃, ppm): δ = 7.64 (dd, J = 7.2, 4.0 Hz, 1H), 7.45 (d, J = 8.0 Hz, 1H), 7.26-7.24 (m, 2H), 2.88 (t, 2H), 1.92-1.87 (m, 2H), 1.03 (t, 3H). ¹³C NMR (100 MHz, CDCl₃, ppm): δ = 167.1, 150.6, 141.3, 123.9, 119.4, 110.3, 30.5, 20.3, 13.9.

2-butylbenzo[d]oxazole¹⁴ (Scheme 5a, entry 6c) (CAS No. 6797-49-5)




Using the experimental procedure EP-2, the product was obtained as light brown liquid in 75%; ¹H NMR (400 MHz, DMSO-d₆, ppm): δ = 7.68 – 7.61 (m, 1H), 7.61 – 7.52 (m, 1H), 7.33 – 7.23 (m, 2H), 2.86 (t, J = 7.5 Hz, 2H), 1.73 (p, J = 7.5 Hz, 2H), 1.33 (dq, J = 14.8, 7.3 Hz, 2H), 0.85 (t, J = 7.4 Hz, 3H). ¹³C NMR (100 MHz, DMSO-d₆, ppm): δ = 166.69, 150.20, 141.02, 124.31, 123.91, 119.07, 110.18, 28.12, 27.35, 21.54, 13.29.

2-neopentylbenzo[d]oxazole¹⁵ (Scheme 5a, entry 6d) (CAS No. 143857-68-5)




Using the experimental procedure EP-2, the product was obtained as light-yellow solid in 70%; ^1H NMR (400 MHz, CDCl_3 , ppm): δ = 7.70 (d, J = 3.2 Hz, 1H), 7.55 – 7.43 (m, 1H), 7.32 – 7.24 (m, 2H), 2.82 (s, 2H), 1.08 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ = 166.05, 150.88, 141.38, 124.52, 124.15, 119.70, 110.40, 42.54, 32.20, 29.73.

2-benzylbenzo[d]oxazole¹⁶ (Scheme 5a, entry 6e) (CAS No. 2008-07-3)




Using the experimental procedure EP-2, the product was obtained as light-yellow solid in 72%; ^1H NMR (400 MHz, CDCl_3 , ppm): δ = 7.67 (dd, J = 5.9, 2.4 Hz, 1H), 7.49 – 7.38 (m, 1H), 7.34 (d, J = 7.1 Hz, 2H), 7.29 (t, J = 7.8 Hz, 2H), 7.24-7.19 (m, 3H), 4.22 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ = 165.18, 151.00, 141.29, 134.76, 128.97, 128.78, 127.27, 124.66, 124.16, 119.77, 110.40, 35.18.

2-(phenoxyethyl)benzo[d]oxazole¹⁷ (Scheme 5a, entry 6f) (CAS No. 7506-48-1)




Using the experimental procedure EP-2, the product was obtained as white solid in 75%; ^1H NMR (400 MHz, CDCl_3 , ppm): δ = 7.65 (dd, J = 5.3, 3.9 Hz, 1H), 7.43 (dd, J = 4.8, 3.2 Hz, 1H), 7.26 – 7.22 (m, 2H), 7.19 (t, J = 7.6 Hz, 2H), 6.97 (s, 1H), 6.94 (s, 1H), 6.92 – 6.85 (m, 1H), 5.20 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ = 161.56, 157.93, 150.97, 140.74, 129.69, 125.64, 124.69, 121.97, 120.43, 114.87, 110.95, 62.80.

2-isopropylbenzo[d]oxazole¹⁴ (Scheme 5a, entry 6g) (CAS No. 6797-15-5)




Using the experimental procedure EP-2, the product was obtained as light brown liquid in 60%; **¹H NMR** (400 MHz, CDCl₃, ppm): δ = 7.70-7.66 (m, 1H), 7.47 (dd, J = 5.6, 3.7 Hz, 1H), 7.35 – 7.23 (m, 2H), 3.25 (hept, J = 7.0 Hz, 1H), 1.46 (d, J = 8.2 Hz, 6H). **¹³C NMR** (100 MHz, CDCl₃, ppm): δ = 171.45, 150.84, 141.27, 124.57, 124.17, 119.72, 110.43, 29.01, 20.41.

2-(tert-butyl)benzo[d]oxazole¹⁴ (Scheme 5a, entry 6h) (CAS No. 54696-03-6)




Using the experimental procedure EP-2, the product was obtained as brown liquid in 58%; **¹H NMR** (400 MHz, CDCl₃, ppm): δ = 7.52-7.48 (m, 1H), 7.30-7.27 (m, 1H), 7.13 – 7.03 (m, 2H), 1.30 (s, 9H). **¹³C NMR** (100 MHz, CDCl₃, ppm): δ = 173.61, 150.94, 141.36, 124.51, 124.08, 119.82, 110.42, 34.28, 28.59.

2-(trichloromethyl)benzo[d]oxazole¹⁷ (Scheme 5a, entry 6i) (CAS No. 14468-53-2)




Using the experimental procedure EP-2, the product was obtained as brown solid in 35%; **¹H NMR** (400 MHz, CDCl₃, ppm): δ = 7.56 (dd, J = 7.9, 1.7 Hz, 1H), 7.19 – 7.08 (m, 1H), 7.03 – 6.87 (m, 1H), 6.89 – 6.76 (m, 1H). **¹³C NMR** (100 MHz, CDCl₃, ppm): δ = 159.31, 149.86, 127.07, 123.84, 123.65, 119.10, 115.61, 92.74.

2-cyclopropylbenzo[d]oxazole¹⁴ (Scheme 5a, entry 6j) (CAS No. 63359-58-0)




Using the experimental procedure EP-2, the product was obtained as brown liquid in 65%; $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): $\delta = 7.58$ (d, $J = 6.7$ Hz, 1H), 7.39 (d, $J = 7.6$ Hz, 1H), 7.23-7.19 (m, 2H), 2.21-2.14 (m, 1H), 1.26-1.21 (m, 2H), 1.23 – 1.07 (m, 2H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): $\delta = 168.64, 150.45, 141.54, 124.11, 123.99, 118.98, 110.02, 9.30, 9.17$.

2-cyclohexylbenzo[d]oxazole¹⁸ (Scheme 5a, entry 6k) (CAS No. 104462-82-0)




Using the experimental procedure EP-2, the product was obtained as brown solid in 57%; $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): $\delta = 7.70 - 7.63$ (m, 1H), 7.63 – 7.55 (m, 1H), 7.35 – 7.24 (m, 2H), 2.92 (tt, $J = 11.0, 3.7$ Hz, 1H), 2.04 (dd, $J = 12.9, 3.1$ Hz, 2H), 1.71 (dt, $J = 13.1, 3.8$ Hz, 2H), 1.65 – 1.50 (m, 3H), 1.35 (qt, $J = 12.2, 3.2$ Hz, 2H), 1.28 – 1.13 (m, 1H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): $\delta = 169.50, 149.99, 140.85, 124.40, 123.96, 119.23, 110.32, 36.78, 29.85, 25.24, 24.82$.

6-chloro-2-methylbenzo[d]oxazole¹¹ (Scheme 5a, entry 6l) (CAS No. 63816-18-2)



Using the experimental procedure EP-2, the product was obtained as brown solid in 57%; $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): $\delta = 7.54$ (dd, $J = 8.4$ Hz, 1H), 7.47 (s, 1H), 7.27 (d, $J = 8.4$ Hz, 1H), 2.63 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): $\delta = 168.9, 146.9, 120.6, 119.5, 107.1, 15.0$.


5-chloro-2-methylbenzo[d]oxazole¹³ (Scheme 5b, entry 6m) (CAS No. 19219-99-9)



Using the experimental procedure EP-2, the product was obtained as light-yellow solid in 74%; $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): $\delta = 7.60$ (s, 1H), 7.36 (d, $J = 8.6$ Hz, 1H), 7.24 (d, $J = 8.6$ Hz, 1H),


2.61 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): $\delta = 165.57, 149.53, 142.31, 129.48, 124.95, 119.39, 111.07, 14.56$.

2-methyl-6-nitrobenzo[d]oxazole¹⁹ (Scheme 5b, entry 6n) (CAS No. 5683-43-2)




Using the experimental procedure EP-2, the product was obtained as off-white solid in 35%; ^1H NMR (400 MHz, CDCl_3 , ppm): $\delta = 8.40$ (s, 1H), 8.28 (d, $J = 8.8$ Hz, 1H), 7.75 (d, $J = 8.8$ Hz, 1H), 2.73 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): $\delta = 168.97, 150.28, 146.98, 120.57, 119.53, 107.06, 15.02$.

2,5-dimethylbenzo[d]oxazole¹³ (Scheme 5b, entry 6o) (CAS No. 5676-58-4)




Using the experimental procedure EP-2, the product was obtained as yellow liquid in 80%; ^1H NMR (400 MHz, CDCl_3 , ppm): $\delta = 7.41$ (s, 1H), 7.31 (d, $J = 8.2$ Hz, 1H), 7.06 (d, $J = 10.1$ Hz, 1H), 2.59 (s, 3H), 2.42 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): $\delta = 163.99, 149.21, 141.51, 133.97, 125.56, 119.33, 109.60, 21.43, 14.51$.

2,6-dimethylbenzo[d]oxazole¹³ (Scheme 5b, entry 6p) (CAS No. 53012-61-6)




Using the experimental procedure EP-2, the product was obtained as yellow liquid in 81%; ^1H NMR (400 MHz, CDCl_3 , ppm): $\delta = 7.48$ (d, $J = 8.2$ Hz, 1H), 7.22 (s, 1H), 7.06 (d, $J = 8.3$ Hz, 1H), 2.56 (s, 3H), 2.42 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , ppm): $\delta = 163.28, 151.20, 139.05, 134.76, 125.26, 118.62, 110.40, 21.58, 14.37$.

5-(tert-butyl)-2-methylbenzo[d]oxazole²⁰ (Scheme 5b, entry 6q) (CAS No. 40874-54-2)




Using the experimental procedure EP-2, the product was obtained as yellow liquid in 79%; $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): $\delta = 7.70$ (s, 1H), 7.44 – 7.34 (m, 2H), 2.65 (s, 3H), 1.40 (s, 9H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): $\delta = 164.12, 149.04, 147.85, 141.23, 122.26, 116.00, 109.45, 34.97, 31.89, 14.59$.

2-methyloxazolo[4,5-b]pyridine¹³ (Scheme 5b, entry 6r) (CAS No. 86467-39-2)




Using the experimental procedure EP-2, the product was obtained as off-white solid in 49%; $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): $\delta = 7.84$ (d, $J = 6.2$ Hz, 1H), 7.37 (d, $J = 8.2$ Hz, 1H), 7.12 (dd, $J = 8.1, 4.6$ Hz, 1H), 2.29 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): $\delta = 172.13, 145.36, 140.59, 138.15, 128.68, 122.86, 23.46$.

2-methylnaphtho[1,2-d]oxazole²¹ (Scheme 5b, entry 6s) (CAS No. 85-15-4)




Using the experimental procedure EP-2, the product was obtained as brown liquid in 55%; $^1\text{H NMR}$ (400 MHz, CDCl_3 , ppm): $\delta = 8.46$ (d, $J = 8.2$ Hz, 1H), 7.93 (d, $J = 8.2$ Hz, 1H), 7.72 (d, $J = 8.8$ Hz, 1H), 7.67 – 7.58 (m, 2H), 7.51 (t, $J = 7.6$ Hz, 1H), 2.72 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , ppm): $\delta = 162.94, 148.18, 136.63, 131.10, 128.58, 126.98, 126.31, 125.35, 125.19, 122.00, 110.70, 14.68$.

2-methylbenzo[d]thiazole¹⁶ (Scheme 5b, entry 6t) (CAS No. 120-75-2)



Using the experimental procedure EP-2, the product was obtained as brown liquid in 75%; $^1\text{H NMR}$ (400 MHz, DMSO- d_6 , ppm): δ = 8.00-7.97 (m, 1H), 7.93 – 7.90 (m, 1H), 7.47-7.43 (m, 1H), 7.39-7.34 (m, 1H), 2.77 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, DMSO- d_6 , ppm): δ = 166.8, 153.0, 135.2, 125.9, 124.6, 121.9, 121.8, 19.6.

5-chloro-2-methylbenzo[d]thiazole¹⁶ (Scheme 5b, entry 6u) (CAS No. 1006-99-1)



Using the experimental procedure EP-2, the product was obtained as brown liquid in 70%; $^1\text{H NMR}$ (400 MHz, DMSO- d_6 , ppm): δ = 8.06 (d, J = 8.6 Hz, 1H), 7.97 (d, J = 2.0 Hz, 1H), 7.43 (dd, J = 8.6, 2.1 Hz, 1H), 2.80 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, DMSO- d_6 , ppm): δ = 169.63, 153.84, 133.96, 130.73, 124.78, 123.38, 121.40, 19.80.

6.0 References

- (1) Qu, E.; Li, S.; Bai, J.; Zheng, Y.; Li, W. Nickel-Catalyzed Reductive Cross-Coupling of N-Acyl and N-Sulfonyl Benzotriazoles with Diverse Nitro Compounds: Rapid Access to Amides and Sulfonamides. *Org. Lett.* **2022**, *24* (1), 58–63. <https://doi.org/10.1021/acs.orglett.1c03535>.
- (2) Jain, I.; Sharma, R.; Malik, P. Manganese-Mediated Acetylation of Alcohols, Phenols, Thiols, and Amines Utilizing Acetic Anhydride. *Synth. Commun.* **2019**. <https://doi.org/10.1080/00397911.2019.1650282>.
- (3) Yi, X.; Yi, X.; Lei, S.; Liu, W.; Che, F.; Yu, C.; Liu, X.; Wang, Z.; Zhou, X.; Zhang, Y. Copper-Catalyzed Radical N-Demethylation of Amides Using N-Fluorobenzenesulfonimide as an Oxidant. *Org. Lett.* **2020**. <https://doi.org/10.1021/acs.orglett.0c00863>.
- (4) Ning, Y.; Wang, S.; Li, M.; Han, J.; Zhu, C.; Xie, J. Site-Specific Umpolung Amidation of Carboxylic Acids via Triplet Synergistic Catalysis. *Nat. Commun.* **2021**. <https://doi.org/10.1038/s41467-021-24908-w>.

- (5) Kumar, V.; Dhawan, S.; Girase, P. S.; Singh, P.; Karpoormath, R. An Environmentally Benign, Catalyst-Free N–C Bond Cleavage/Formation of Primary, Secondary, and Tertiary Unactivated Amides. *European J. Org. Chem.* **2021**. <https://doi.org/10.1002/ejoc.202101114>.
- (6) Leong, B. X.; Teo, Y. C.; Condamines, C.; Yang, M. C.; Su, M. Der; So, C. W. A NHC-Silyliumylidene Cation for Catalytic N-formylation of Amines Using Carbon Dioxide. *ACS Catal.* **2020**. <https://doi.org/10.1021/acscatal.0c03795>.
- (7) Jiang, J.; Li, L.; Zhang, L.; Chen, Q.; Sun, H.; Liao, S.; Li, C.; Zhang, L. Organophosphoric Acid Promoted Transamidation: Using N,N-Dimethylformamide and N,N-Dimethylacetamide as the Acyl Sources. *ChemistrySelect* **2021**, 6 (45), 12834–12837. <https://doi.org/https://doi.org/10.1002/slct.202103932>.
- (8) Kandula, V.; Gudipati, R.; Chatterjee, A.; Yennam, S.; Behera, M. An Efficient Method for the Preparation of N -Formamides Using Propylphosphonic Anhydride (T3P®). *SynOpen* **2018**. <https://doi.org/10.1055/s-0036-1591584>.
- (9) Dhawan, S.; Girase, P. S.; Kumar, V.; Karpoormath, R. HCl-Mediated Transamidation of Unactivated Formamides Using Aromatic Amines in Aqueous Media. *Synth. Commun.* **2021**. <https://doi.org/10.1080/00397911.2021.1989597>.
- (10) Jiang, X.; Huang, Z.; Makha, M.; Du, C. X.; Zhao, D.; Wang, F.; Li, Y. Tetracoordinate Borates as Catalysts for Reductive Formylation of Amines with Carbon Dioxide. *Green Chem.* **2020**. <https://doi.org/10.1039/d0gc01741h>.
- (11) Sutar, S. M.; Kalkhambkar, R. G. Ultrasonic Assisted Facile Synthesis of N-Arylamides Using Nitriles and 1-Aryltriazenes Precursors Promoted by Brønsted Acidic Ionic Liquid under Metal-Free Conditions. *ChemistrySelect* **2021**. <https://doi.org/10.1002/slct.202101855>.
- (12) Zhou, X. Y.; Chen, X.; Yang, D. Iodine and Brønsted Acid Catalyzed C–C Bond Cleavage of 1,3-Diketones for the Acylation of Amines. *Synth. Commun.* **2020**. <https://doi.org/10.1080/00397911.2019.1691736>.


- (13) Mayo, M. S.; Yu, X.; Zhou, X.; Feng, X.; Yamamoto, Y.; Bao, M. Synthesis of Benzoxazoles from 2-Aminophenols and β -Diketones Using a Combined Catalyst of Brønsted Acid and Copper Iodide. *J. Org. Chem.* **2014**. <https://doi.org/10.1021/jo500604x>.
- (14) Niu, Z. J.; Li, L. H.; Liu, X. Y.; Liang, Y. M. Transition-Metal-Free Alkylation/Arylation of Benzoxazole via Tf₂O-Activated-Amide. *Adv. Synth. Catal.* **2019**. <https://doi.org/10.1002/adsc.201901078>.
- (15) Dong, K.; Humeidi, A.; Griffith, W.; Arman, H.; Xu, X.; Doyle, M. P. Ag I -Catalyzed Reaction of Enol Diazoacetates and Imino Ethers: Synthesis of Highly Functionalized Pyrroles. *Angew. Chemie* **2021**. <https://doi.org/10.1002/ange.202101641>.
- (16) Zhang, J.; Hu, L.; Liu, Y.; Zhang, Y.; Chen, X.; Luo, Y.; Peng, Y.; Han, S.; Pan, B. Elemental Sulfur-Promoted Benzoxazole/Benzothiazole Formation Using a C=C Double Bond as a One-Carbon Donator. *J. Org. Chem.* **2021**. <https://doi.org/10.1021/acs.joc.1c01357>.
- (17) Luo, B.; Li, D.; Zhang, A. L.; Gao, J. M. Synthesis, Antifungal Activities and Molecular Docking Studies of Benzoxazole and Benzothiazole Derivatives. *Molecules* **2018**. <https://doi.org/10.3390/molecules23102457>.
- (18) Putta, R. R.; Chun, S.; Choi, S. H.; Lee, S. B.; Oh, D. C.; Hong, S. Iron(0)-Catalyzed Transfer Hydrogenative Condensation of Nitroarenes with Alcohols: A Straightforward Approach to Benzoxazoles, Benzothiazoles, and Benzimidazoles. *J. Org. Chem.* **2020**. <https://doi.org/10.1021/acs.joc.0c02191>.
- (19) Zhang, P.; Cedilote, M.; Cleary, T. P.; Pierce, M. E. Mono-Nitration of Aromatic Compounds via Their Nitric Acid Salts. *Tetrahedron Lett.* **2007**. <https://doi.org/10.1016/j.tetlet.2007.10.027>.
- (20) Li, K. L.; Du, Z. B.; Guo, C. C.; Chen, Q. Y. Regioselective Syntheses of 2- and 4-Formylpyrido[2,1-b]Benzoxazoles. *J. Org. Chem.* **2009**. <https://doi.org/10.1021/jo900267c>.

(21) Katritzky, A. R.; Wang, Z.; Hall, C. D.; Akhmedov, N. G.; Shestopalov, A. A.; Steel, P. J.



Cyclization of α -Oxo-Oximes to 2-Substituted Benzoxazoles. *J. Org. Chem.* **2003**.


<https://doi.org/10.1021/jo026771y>.

7.0 Copies of ^1H and ^{13}C spectra




^1H NMR spectrum of 3A







¹³C NMR spectrum of 3B




¹H NMR spectrum of 3C




¹³C NMR spectrum of 3C




¹H NMR spectrum of 3D




¹³C NMR spectrum of 3D




¹H NMR spectrum of 3E




¹³C NMR spectrum of **3E**




¹H NMR spectrum of **3F**




¹³C NMR spectrum of **3F**




¹H NMR spectrum of **3G**




^{13}C NMR spectrum of 3G




^1H NMR spectrum of 3H




¹³C NMR spectrum of **3H**




¹³C NMR spectrum of **3H**




¹H NMR spectrum of **3I**




¹³C NMR spectrum of **3I**




¹H NMR spectrum of 3J




¹³C NMR spectrum of 3J




¹H NMR spectrum of 3K




¹³C NMR spectrum of 3K




¹H NMR spectrum of 3a




¹³C NMR spectrum of 3a




¹H NMR spectrum of 3b




¹³C NMR spectrum of 3b




¹H NMR spectrum of 3c




¹³C NMR spectrum of 3c




¹H NMR spectrum of 3d




¹³C NMR spectrum of 3d




¹H NMR spectrum of 3e




¹³C NMR spectrum of 3e




¹H NMR spectrum of 3f




¹³C NMR spectrum of 3f




¹H NMR spectrum of 3g




¹³C NMR spectrum of 3g




¹H NMR spectrum of **3h**




¹³C NMR spectrum of **3h**




¹H NMR spectrum of 3i




¹³C NMR spectrum of 3i




¹H NMR spectrum of 3j




¹³C NMR spectrum of 3j




¹H NMR spectrum of **3k**




¹³C NMR spectrum of **3k**




¹H NMR spectrum of 3I





¹³C NMR spectrum of 3I




¹H NMR spectrum of 3m




¹³C NMR spectrum of 3m







^1H NMR spectrum of **3p**




^{13}C NMR spectrum of **3p**




¹H NMR spectrum of 3q




¹³C NMR spectrum of 3q




¹H NMR spectrum of **3r**




¹³C NMR spectrum of **3r**




¹H NMR spectrum of 3s




¹³C NMR spectrum of 3s




¹H NMR spectrum of 3t




¹³C NMR spectrum of 3t




¹H NMR spectrum of 3u




¹³C NMR spectrum of 3u




¹H NMR spectrum of 3v




¹³C NMR spectrum of 3v




¹H NMR spectrum of 3w




¹³C NMR spectrum of 3w




¹H NMR spectrum of 3x




¹³C NMR spectrum of 3x




^1H NMR spectrum of 3y





^{13}C NMR spectrum of 3y






¹H NMR spectrum of 3z




¹³C NMR spectrum of 3z










^1H NMR spectrum of **3ad**




^{13}C NMR spectrum of **3ad**








¹H NMR spectrum of **3af**




¹³C NMR spectrum of **3af**







^1H NMR spectrum of 6a





^{13}C NMR spectrum of 6a






^1H NMR spectrum of **6b**




^{13}C NMR spectrum of **6b**












¹H NMR spectrum of 6e




¹³C NMR spectrum of 6e













¹H NMR spectrum of 6h




¹³C NMR spectrum of 6h










¹H NMR spectrum of 6l



¹³C NMR spectrum of 6k

